A controversial technique has been devised to treat fetal stage fetal organ failure, with potential applications for organ transplants.
The National Institute of Allergy and Infectious Diseases has developed a test to identify fetuses with a condition that causes an organ failure and then inject them with a cocktail of drugs that would cause a condition known as fetalis.
The test, called fetal stage organ failure (FSP), is being developed as a way of helping patients with FSP and other organ failure conditions, which are increasingly common.
The drug is being tested by the US National Institutes of Health (NIH) in partnership with the University of Florida.FSP can be triggered by a single dose of the drug, or it can be administered multiple times, using an array of combinations.
The drug, called nefibrotine, has been shown to be safe and effective in other types of FSP, such as the one that occurs in the fetus.
The NIH, which has not yet approved the drug for use in humans, is using the test to test whether it is safe and can be used in the first trimester of pregnancy, before fetuses have developed fully.
Fernando Dominguez, who heads the NIH’s Center for Prenatal Diagnostics and is the lead author of the study, said it is the first drug to be developed for FSP that is able to kill fetal stage organs in humans.
“The potential for using this new test to prevent and treat fetal organ loss is great, and it will allow us to improve the safety of this treatment,” he said.
Dominguez said there was no reason to expect it would not be used for other organ failures in the future.
“We can’t predict how many patients will benefit from this treatment, but we can safely conclude that there is very good reason to use this drug for this condition,” he added.
The technique involves taking a small amount of a drug that mimics the effects of the organ failure protein.
When injected into the bloodstream, the drug binds to the cell wall of the fetus, causing it to release an enzyme that breaks down the organ.
This breaks down tissue, releasing the drug.
The effect of the drugs is that they stop the formation of new organs, and stop the production of abnormal proteins in the tissue.
It is hoped this may eventually lead to the development of drugs to prevent organ failure in fetuses.
In a statement, the National Institutes said it has a long history of testing the effectiveness of drug cocktails against organ failure.
“Our goal is to help patients with all types of organ failure to live normal lives, and we are continually looking for ways to advance the research and development of our new therapies,” said NIA director Mark McCaw.